[ibd-display-video id=2102289 width=50 float=left autostart=true] This proprietary rating tracks technical performance by using a 1 (worst) to 99 (best) score that shows how a stock's price performance over the last 52 weeks compares to the rest of the market.
Over 100 years of market history shows that the best stocks tend to have an RS Rating north of 80 as they launch their biggest climbs. See if Portola Pharmaceuticals can continue to show renewed price strength and hit that benchmark.
Portola Pharmaceuticals is now considered extended and out of buy range after clearing a 41.37 buy point in a first-stage flat base . See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week moving average.
Earnings growth rose last quarter from 0% to 14%. But sales fell from -10% to -59%. Look for the next report on or around Feb. 28.
Portola Pharmaceuticals holds the No. 231 rank among its peers in the Medical-Biomed/Biotech industry group. Bioverativ ( BIVV ), Vertex Pharmaceuticals ( VRTX ) and Enanta Pharmaceuticals ( ENTA ) are among the top 5 highly rated stocks within the group.